Cristian Waitman

Cristian Waitman

Auto-generated profile, based on publicly available information

Cristian Waitman

Universidad Siglo XXI, Córdoba, Argentina

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2020 in Journal of Medical Internet Research
Verified
Journal Article
Open access
EGEmilio Goldenhersch
Emilio Goldenhersch
Johannes ThrulJohannes Thrul
Johannes Thrul
JUJoaquín Ungaretti
Joaquín Ungaretti
NRNicolas Rosencovich
Nicolas Rosencovich
CWCristian Waitman
Cristian Waitman
MCMarcelo Rodriguez Ceberio
Marcelo Rodriguez Ceberio
Background: Obstacles to current tobacco cessation programs include limited access and adherence to effective interventions. Digital interventions offer a great opportunity to overcome these difficulties, yet virtual reality has not been used as a remote and self-administered tool to help increase adherence and effectiveness of digital interventions for tobacco cessation. Objective: This study aimed to evaluate participant adherence and smoking cessation outcomes in a pilot randomized controlled trial of the digital intervention Mindcotine (MindCotine Inc) using a self-administered treatment of virtual reality combined with mindfulness. Methods: A sample of 120 participants was recruited in the city of Buenos Aires, Argentina (mean age 43.20 years, SD 9.50; 57/120, 47.5% female). Participants were randomly assigned to a treatment group (TG), which received a self-assisted 21-day program based on virtual reality mindful exposure therapy (VR-MET) sessions, daily surveys, and online peer-to-peer support moderated by psychologists, or a control group (CG), which received the online version of the smoking cessation manual from the Argentine Ministry of Health. Follow-up assessments were conducted by online surveys at postintervention and 90-day follow-up. The primary outcome was self-reported abstinence at postintervention, with missing data assumed as still smoking. Secondary outcomes included sustained abstinence at 90-day follow-up, adherence to the program, and readiness to quit. Results: Follow-up rates at day 1 were 93% (56/60) for the TG and 100% (60/60) for the CG. At postintervention, the TG reported 23% (14/60) abstinence on that day compared with 5% (3/60) in the CG. This difference was statistically significant (χ21=8.3; P=.004). The TG reported sustained abstinence of 33% (20/60) at 90 days. Since only 20% (12/60) of participants in the CG completed the 90-day follow-up, we did not conduct a statistical comparison between groups at this follow-up time point. Among participants still smoking at postintervention, the TG was significantly more ready to quit compared to the CG (TG: mean 7.71, SD 0.13; CG: mean 7.16, SD 0.13; P=.005). A total of 41% (23/56) of participants completed the treatment in the time frame recommended by the program. Conclusions: Results provide initial support for participant adherence to and efficacy of Mindcotine and warrant testing the intervention in a fully powered randomized trial. However, feasibility of trial follow-up assessment procedures for control group participants needs to be improved. Further research is needed on the impact of VR-MET on long-term outcomes. Trial Registration: ISRCTN Registry ISRCTN50586181; http://www.isrctn.com/ISRCTN50586181

23 July 2024 in JMIR Formative Research
Verified
Journal Article
Open access
RJRiley Walton Jackson
Riley Walton Jackson
ACAnn Cao-Nasalga
Ann Cao-Nasalga
ACAmy Chieng
Amy Chieng
APAmy Pirkl
Amy Pirkl
AJAnnemarie Jagielo
Annemarie Jagielo
Judith J. ProchaskaJudith J. Prochaska
Judith J. Prochaska
Background: Smoking contributes to 1 in 3 cancer deaths. At the Stanford Cancer Center, tobacco cessation medication management and counseling are provided as a covered benefit. Patients charted as using tobacco are contacted by a tobacco treatment specialist and offered cessation services. As a novel addition, this study examined the acceptability of a virtual reality (VR) mindful exposure therapy app for quitting smoking called MindCotine. Objective: The objective of this study was to determine the feasibility and acceptability of offering 6 weeks of MindCotine treatment as a part of Stanford’s Tobacco Treatment Services for patients seen for cancer care. Methods: As part of a single-group pilot study, the MindCotine VR program was offered to English- or Spanish-speaking patients interested in quitting smoking. Given the visual interface, epilepsy was a medical exclusion. Viewed from a smartphone with an attachable VR headset, MindCotine provides a digital environment with audiovisual content guiding mindfulness exercises (eg, breathing techniques, body awareness, and thought recognition), text-based coaching, and cognitive behavioral therapy-based self-reflections for quitting smoking. Interested patients providing informed consent were mailed a MindCotine headset and asked to use the app for 10+ minutes a day. At the end of 6 weeks, participants completed a feedback survey. Results: Of the 357 patients reached by the tobacco treatment specialist, 62 (17.3%) were ineligible, 190 (53.2%) were not interested in tobacco treatment services, and 78 (21.8%) preferred other tobacco treatment services. Among the 105 eligible and interested in assistance with quitting, 27 (25.7%) were interested in MindCotine, of whom 20 completed the informed consent, 9 used the program, and 8 completed their end-of-treatment survey. Participants using MindCotine completed, on average, 13 (SD 20.2) program activities, 19 (SD 26) journal records, and 11 (SD 12.3) coaching engagements. Of the 9 participants who used MindCotine, 4 (44%) reported some dizziness with app use that resolved and 7 (78%) would recommend MindCotine to a friend. In total, 2 participants quit tobacco (22.2% reporting, 10% overall), 2 others reduced their smoking by 50% or more, and 2 quit for 24 hours and then relapsed. Conclusions: In a feasibility and acceptability pilot study of a novel VR tobacco treatment app offered to patients at a cancer center, 4 of 9 (44%) reporting and 4 of 20 (20%) overall substantially reduced or quit using tobacco after 6 weeks and most would recommend the app to others. Further testing on a larger sample is warranted. Trial Registration: ClinicalTrials.gov NCT05220254; https://clinicaltrials.gov/study/NCT05220254

21 December 2019 in JMIR Preprints
Verified
Preprint
Open access
EGEmilio Goldenhersch
Emilio Goldenhersch
Johannes ThrulJohannes Thrul
Johannes Thrul
JUJoaquín Ungaretti
Joaquín Ungaretti
NRNicolas Rosencovich
Nicolas Rosencovich
CWCristian Waitman
Cristian Waitman
MCMarcelo Rodriguez Ceberio
Marcelo Rodriguez Ceberio
BACKGROUND Obstacles to current tobacco cessation programs include limited access and adherence to effective interventions. Digital interventions offer a great opportunity to overcome these difficulties, yet virtual reality has not been used as a remote and self-administered tool to help increase adherence and effectiveness of digital interventions for tobacco cessation. OBJECTIVE This study aimed to evaluate participant adherence and smoking cessation outcomes in a pilot randomized controlled trial of the digital intervention Mindcotine (MindCotine Inc) using a self-administered treatment of virtual reality combined with mindfulness. METHODS A sample of 120 participants was recruited in the city of Buenos Aires, Argentina (mean age 43.20 years, SD 9.50; 57/120, 47.5% female). Participants were randomly assigned to a treatment group (TG), which received a self-assisted 21-day program based on virtual reality mindful exposure therapy (VR-MET) sessions, daily surveys, and online peer-to-peer support moderated by psychologists, or a control group (CG), which received the online version of the smoking cessation manual from the Argentine Ministry of Health. Follow-up assessments were conducted by online surveys at postintervention and 90-day follow-up. The primary outcome was self-reported abstinence at postintervention, with missing data assumed as still smoking. Secondary outcomes included sustained abstinence at 90-day follow-up, adherence to the program, and readiness to quit. RESULTS Follow-up rates at day 1 were 93% (56/60) for the TG and 100% (60/60) for the CG. At postintervention, the TG reported 23% (14/60) abstinence on that day compared with 5% (3/60) in the CG. This difference was statistically significant (χ21=8.3; P=.004). The TG reported sustained abstinence of 33% (20/60) at 90 days. Since only 20% (12/60) of participants in the CG completed the 90-day follow-up, we did not conduct a statistical comparison between groups at this follow-up time point. Among participants still smoking at postintervention, the TG was significantly more ready to quit compared to the CG (TG: mean 7.71, SD 0.13; CG: mean 7.16, SD 0.13; P=.005). A total of 41% (23/56) of participants completed the treatment in the time frame recommended by the program. CONCLUSIONS Results provide initial support for participant adherence to and efficacy of Mindcotine and warrant testing the intervention in a fully powered randomized trial. However, feasibility of trial follow-up assessment procedures for control group participants needs to be improved. Further research is needed on the impact of VR-MET on long-term outcomes. CLINICALTRIAL ISRCTN Registry ISRCTN50586181; http://www.isrctn.com/ISRCTN50586181

21 August 2026 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
HHHoulin Hong
Houlin Hong
MLMatthew R Lootens
Matthew R Lootens
RBRebecca Bachman
Rebecca Bachman
LLLuis David Olivera Leon
Luis David Olivera Leon
ADAnn F Dunlap
Ann F Dunlap
Terry HuangTerry Huang
Terry Huang
Background: Young adults experience disproportionately high levels of stress, creating significant health challenges. This demographic often underuses traditional stress management methods due to perceived ineffectiveness, inconvenience, or stigma. Given these challenges, mobile virtual reality (VR) offers a novel, engaging, and accessible alternative stress management tool that may be more appealing to young adults. Objective: This pilot randomized controlled trial (RCT) evaluated the preliminary effects of MindCo Relief (MR), a mobile VR-based stress management app, accompanied by online coaching, on perceived stress, resilience, anxiety, depressive symptoms, and quality of life (QoL). Methods: Young adults aged 18 to 29 years were recruited to participate in the study. A total of 70 participants with moderate-to-high stress levels at baseline were randomized to an intervention (n=34) group and a control (n=36) group. Moderate-to-high stress was defined as a sum score of 14 or more on the Perceived Stress Scale–10 (PSS-10). The intervention group completed an 8-week VR mindfulness program with access to in-person coaching, while the control group received no intervention. The primary outcome was self-reported perceived stress (PSS-10). Secondary measures included resilience (measured by the Connor-Davidson Resilience Scale–2), anxiety (measured by the Generalized Anxiety Disorder–7 scale), depressive symptoms (measured by the Patient Health Questionnaire–9), and QoL (measured by the General Well-Being Schedule). Primary analyses used linear mixed-effects models to assess the intervention effect over the 8-week study period. Secondary analyses examined whether the percentage of program modules completed and the number of coaching sessions attended were associated with changes in the primary and secondary outcomes. Results: The mean age of the participants was 23 (SD 3.41) years, and they were predominantly female (n=52, 74%), students (n=46, 66%), and insured (n=63, 90%). No significant differences were observed between the intervention and control groups in terms of sex (P=.89), student status (P=.56), insurance status (P=.68), race and ethnicity (P=.18), or age (P=.32). Linear mixed-effects models showed a significant interaction between time and intervention, with the intervention group showing greater reductions in stress (β=−3.84, SE 1.37; P=.007), anxiety (β=−3.21, SE 0.97; P=.002), and depressive symptoms (β=−3.13, SE 1.13; P=.007) and a greater increase in QoL (β=9.99, SE 2.92; P=.001). No significant interaction was found for resilience (β=0.83, SE 0.43; P=.06). In the secondary analyses, neither the percentage of modules completed nor the number of coaching sessions attended was significantly associated with changes in the primary or secondary outcomes. Conclusions: This study provided preliminary evidence that mobile VR can help reduce stress among young adults by providing immersive environments that promote relaxation and adaptive stress responses. The findings support further exploration of VR’s role in mental health care. Future research should examine the efficacy and long-term effects of this mobile VR software using larger, more diverse samples. Strategies to sustain VR engagement are also warranted. Trial Registration: ClinicalTrials.gov NCT06970652; https://clinicaltrials.gov/study/NCT06970652

22 November 2023 in JMIR Preprints
Verified
Preprint
Open access
RJRiley Walton Jackson
Riley Walton Jackson
ACAnn Cao-Nasalga
Ann Cao-Nasalga
ACAmy Chieng
Amy Chieng
APAmy Pirkl
Amy Pirkl
AJAnnemarie Jagielo
Annemarie Jagielo
Judith J. ProchaskaJudith J. Prochaska
Judith J. Prochaska
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Smoking contributes to 1 in 3 cancer deaths. At the Stanford Cancer Center, tobacco cessation medication management and counseling are provided as a covered benefit. Patients charted as using tobacco are contacted by a tobacco treatment specialist and offered cessation services. As a novel addition, this study examined the acceptability of a virtual reality (VR) mindful exposure therapy app for quitting smoking called MindCotine. Objective: The objective of this study was to determine the feasibility and acceptability of offering 6 weeks of MindCotine treatment as a part of Stanford’s Tobacco Treatment Services for patients seen for cancer care. Methods: As part of a single-group pilot study, the MindCotine VR program was offered to English- or Spanish-speaking patients interested in quitting smoking. Given the visual interface, epilepsy was a medical exclusion. Viewed from a smartphone with an attachable VR headset, MindCotine provides a digital environment with audiovisual content guiding mindfulness exercises (eg, breathing techniques, body awareness, and thought recognition), text-based coaching, and cognitive behavioral therapy-based self-reflections for quitting smoking. Interested patients providing informed consent were mailed a MindCotine headset and asked to use the app for 10+ minutes a day. At the end of 6 weeks, participants completed a feedback survey. Results: Of the 357 patients reached by the tobacco treatment specialist, 62 (17.3%) were ineligible, 190 (53.2%) were not interested in tobacco treatment services, and 78 (21.8%) preferred other tobacco treatment services. Among the 105 eligible and interested in assistance with quitting, 27 (25.7%) were interested in MindCotine, of whom 20 completed the informed consent, 9 used the program, and 8 completed their end-of-treatment survey. Participants using MindCotine completed, on average, 13 (SD 20.2) program activities, 19 (SD 26) journal records, and 11 (SD 12.3) coaching engagements. Of the 9 participants who used MindCotine, 4 (44%) reported some dizziness with app use that resolved and 7 (78%) would recommend MindCotine to a friend. In total, 2 participants quit tobacco (22.2% reporting, 10% overall), 2 others reduced their smoking by 50% or more, and 2 quit for 24 hours and then relapsed. Conclusions: In a feasibility and acceptability pilot study of a novel VR tobacco treatment app offered to patients at a cancer center, 4 of 9 (44%) reporting and 4 of 20 (20%) overall substantially reduced or quit using tobacco after 6 weeks and most would recommend the app to others. Further testing on a larger sample is warranted. Trial Registration: ClinicalTrials.gov NCT05220254; https://clinicaltrials.gov/study/NCT05220254

5 September 2025 in JMIR Preprints
Verified
Preprint
Open access
HHHoulin Hong
Houlin Hong
MLMatthew R Lootens
Matthew R Lootens
RBRebecca Bachman
Rebecca Bachman
LLLuis David Olivera Leon
Luis David Olivera Leon
ADAnn F Dunlap
Ann F Dunlap
Terry HuangTerry Huang
Terry Huang
BACKGROUND Young adults experience disproportionately high levels of stress, creating significant health challenges. This demographic often underuses traditional stress management methods due to perceived ineffectiveness, inconvenience, or stigma. Given these challenges, mobile virtual reality (VR) offers a novel, engaging, and accessible alternative stress management tool that may be more appealing to young adults. OBJECTIVE This pilot randomized controlled trial (RCT) evaluated the preliminary effects of MindCo Relief (MR), a mobile VR-based stress management app, accompanied by online coaching, on perceived stress, resilience, anxiety, depressive symptoms, and quality of life (QoL). METHODS Young adults aged 18 to 29 years were recruited to participate in the study. A total of 70 participants with moderate-to-high stress levels at baseline were randomized to an intervention (n=34) group and a control (n=36) group. Moderate-to-high stress was defined as a sum score of 14 or more on the Perceived Stress Scale–10 (PSS-10). The intervention group completed an 8-week VR mindfulness program with access to in-person coaching, while the control group received no intervention. The primary outcome was self-reported perceived stress (PSS-10). Secondary measures included resilience (measured by the Connor-Davidson Resilience Scale–2), anxiety (measured by the Generalized Anxiety Disorder–7 scale), depressive symptoms (measured by the Patient Health Questionnaire–9), and QoL (measured by the General Well-Being Schedule). Primary analyses used linear mixed-effects models to assess the intervention effect over the 8-week study period. Secondary analyses examined whether the percentage of program modules completed and the number of coaching sessions attended were associated with changes in the primary and secondary outcomes. RESULTS The mean age of the participants was 23 (SD 3.41) years, and they were predominantly female (n=52, 74%), students (n=46, 66%), and insured (n=63, 90%). No significant differences were observed between the intervention and control groups in terms of sex (P=.89), student status (P=.56), insurance status (P=.68), race and ethnicity (P=.18), or age (P=.32). Linear mixed-effects models showed a significant interaction between time and intervention, with the intervention group showing greater reductions in stress (β=−3.84, SE 1.37; P=.007), anxiety (β=−3.21, SE 0.97; P=.002), and depressive symptoms (β=−3.13, SE 1.13; P=.007) and a greater increase in QoL (β=9.99, SE 2.92; P=.001). No significant interaction was found for resilience (β=0.83, SE 0.43; P=.06). In the secondary analyses, neither the percentage of modules completed nor the number of coaching sessions attended was significantly associated with changes in the primary or secondary outcomes. CONCLUSIONS This study provided preliminary evidence that mobile VR can help reduce stress among young adults by providing immersive environments that promote relaxation and adaptive stress responses. The findings support further exploration of VR’s role in mental health care. Future research should examine the efficacy and long-term effects of this mobile VR software using larger, more diverse samples. Strategies to sustain VR engagement are also warranted. CLINICALTRIAL ClinicalTrials.gov NCT06970652; https://clinicaltrials.gov/study/NCT06970652